An independent retrospective study also suggests that TP53 mutation in MDS may predict complete response (CR) to decitabine, but in this report, TP53 mutation was associated with a shorter OS, even among patients with CR (14 vs. 39 months, p = 0.012) [39]. Here, TP53 is linked to myelodysplastic syndrome.